You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 4,215,104


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,215,104
Title: Multi-fractionable tablet structure
Abstract:The invention disclosed provides a multi-fractionable tablet structure initially configurated in a unitary dosage while having readily severable sub-dosage units as components thereof. Score markings are positioned variously about the tablet both along the top and bottom surfaces of an approximately rectangular configuration whereas in preferred embodiments thereof, score markings additionally appear along opposite vertical side surfaces of the tablet. Special placement of the score markings readily permit at least either an accurate bisectional fracture or accurate trisectional fracture of the tablet as may be desired for patient consumption.
Inventor(s): Ullman; Michael K. (Evansville, IN), David; Stephen T. (Evansville, IN), Gallian; Claude E. (Evansville, IN)
Assignee: Mead Johnson & Company (Evansville, IN)
Application Number:06/024,139
Patent Claim Types:
see list of patent claims
Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of U.S. Patent 4,215,104: A Detailed Analysis

Introduction

When analyzing a patent, it is crucial to understand the scope and claims as they define the protection and boundaries of the invention. Here, we will delve into the specifics of U.S. Patent 4,215,104, although the exact details of this patent are not provided in the sources. We will use general principles and guidelines to illustrate how one would conduct such an analysis.

Patent Claims: Definition and Importance

Patent claims are the heart of a patent application, defining the matter for which protection is sought. According to the USPTO, claims must be clear, concise, and fully supported by the description provided in the patent application[5].

Structure of Patent Claims

  • Independent and Dependent Claims: Independent claims stand alone and define the invention without reference to other claims. Dependent claims, on the other hand, refer back to and further limit an independent claim[5].
  • Claim Language: Claims should be in terms of the technical features of the invention. They often include a statement indicating the prior art features and a characterizing portion that states the novel features for which protection is sought[5].

Measuring Patent Scope

Patent scope is a critical aspect of patent analysis. It can be measured using various metrics such as independent claim length and independent claim count. These metrics have been shown to have explanatory power for several correlates of patent scope, including patent maintenance payments, forward citations, and the breadth of patent classes[3].

Patent Obviousness

The determination of obviousness is a key factor in patent validity. Recently, the Federal Circuit has eliminated "improperly rigid" tests for design patent obviousness, aligning with the more flexible approach established by the Supreme Court in KSR v. Teleflex. This decision implies that the obviousness analysis for design patents will now be more akin to that for utility patents, focusing on a more flexible and case-by-case evaluation[1].

Design Patent Obviousness: The New Landscape

  • Flexible Approach: The Federal Circuit's decision to discard rigid tests like the "basically the same" and "so related" tests means that design patent obviousness will be evaluated with greater flexibility, similar to utility patents[1].
  • Impact on Patent Owners and Applicants: This change is likely to make it easier for competitors to challenge the validity of existing design patents and for examiners to reject claimed designs during prosecution[1].

Subject Matter Eligibility

For patents, especially those involving AI and other emerging technologies, subject matter eligibility is a significant concern. The USPTO's 2024 Guidance Update emphasizes the importance of demonstrating that claims are directed to a specific, concrete technological advancement or solution to a technical problem under Step 2A, Prong Two of the Alice/Mayo framework[4].

Crafting Effective Claims

  • Clarity and Conciseness: Claims must be clear and concise, fully supported by the description in the patent application[5].
  • Practical Applicability: For AI inventions, demonstrating practical applicability and addressing a specific technical problem is crucial for overcoming section 101 rejections[4].

Data and Statistics in Patent Analysis

The USPTO provides extensive datasets, such as the Patent Claims Research Dataset, which contain detailed information on claims from U.S. patents and applications. These datasets can be used to analyze trends in patent scope, claim length, and other metrics that are indicative of patent quality and validity[2].

International Patent Considerations

For patents filed under the Patent Cooperation Treaty (PCT), specific rules govern the number, numbering, and manner of claiming. Claims must be reasonable in number, considering the nature of the invention, and must commence on a new sheet[5].

Key Takeaways

  • Clear and Concise Claims: Ensure that patent claims are clear, concise, and fully supported by the description.
  • Flexible Obviousness Analysis: Design patent obviousness will now be evaluated with a more flexible approach, similar to utility patents.
  • Subject Matter Eligibility: Demonstrate practical applicability and address specific technical problems to overcome section 101 rejections.
  • Patent Scope Metrics: Use metrics like independent claim length and count to measure and analyze patent scope.
  • International Considerations: Adhere to PCT rules for claim structure and formatting.

FAQs

Q: What are the key elements of a patent claim? A: Patent claims must be clear, concise, and fully supported by the description. They should define the matter for which protection is sought and include both prior art features and a characterizing portion[5].

Q: How has the Federal Circuit's decision affected design patent obviousness? A: The Federal Circuit has eliminated "improperly rigid" tests for design patent obviousness, adopting a more flexible approach similar to that for utility patents, as established by the Supreme Court in KSR v. Teleflex[1].

Q: What metrics can be used to measure patent scope? A: Metrics such as independent claim length and independent claim count can be used to measure patent scope and have explanatory power for several correlates of patent scope[3].

Q: How does the USPTO's 2024 Guidance Update impact AI inventions? A: The update clarifies that AI inventions are patentable and emphasizes the importance of demonstrating practical applicability and addressing specific technical problems under Step 2A, Prong Two of the Alice/Mayo framework[4].

Q: What are the requirements for claims in PCT applications? A: Claims in PCT applications must be reasonable in number, considering the nature of the invention, and must commence on a new sheet. They must also adhere to specific rules regarding numbering and formatting[5].

Sources

  1. Full Federal Circuit Eliminates “Improperly Rigid” Tests for Design Patent Obviousness - Ballard Spahr
  2. Patent Claims Research Dataset - USPTO
  3. Patent Claims and Patent Scope - SSRN
  4. The Importance of Prong Two of Step 2A for AI Inventions - Baker Botts
  5. The Claims - USPTO MPEP

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 4,215,104

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.